Dual specificity antibody fusions
The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
1. An albumin binding antibody, comprising the sequence given in SEQ ID NO: 56 for CDR-H1, the sequence given in SEQ ID NO: 57 for CDR-H2, the sequence given in SEQ ID NO: 58 for CDR-H3, the sequence given in SEQ ID NO: 59 for CDR-L1, the sequence given in SEQ ID NO: 60 for CDR-L2, and the sequence given in SEQ ID NO: 61 for CDR-L3.
2. The albumin binding antibody of claim 1 , further comprising a heavy chain VH domain having the sequence given in SEQ ID NO: 52.
3. The albumin binding antibody of claim 2 , further comprising a light chain VL domain having the sequence given in SEQ ID NO: 53.
4. The albumin binding antibody of claim 1 , wherein the antibody is a whole antibody or a functionally active fragment or derivative thereof.
5. The albumin binding antibody of claim 1 , wherein the antibody is a Fab, a modified Fab, a Fab′, a F(ab′)2, Fv, a scFv, a bi, a tri, or a tetra-valent antibody, a Bis-scFv, a diabody, a triabody, a tetrabody, or an epitope-binding fragment thereof.
6. The albumin binding antibody of claim 1 , wherein the antibody is multispecific.
7. The albumin binding antibody of claim 1 , wherein the antibody is conjugated to an antibody, a protein, or a molecule.
8. The albumin binding antibody of claim 1 , wherein the antibody is humanised.
9. The albumin binding antibody of claim 1 , wherein the albumin is human serum albumin.
10. The albumin binding antibody of claim 1 , wherein the antibody has a binding affinity for albumin of about 2 μM or better.
11. A pharmaceutical composition, comprising the albumin binding antibody of claim 1 .
12. The pharmaceutical composition of claim 11 , wherein the composition is for the treatment of a disease or disorder;
wherein the disease or disorder is an inflammatory disease or disorder, an immune disease or disorder, a fibrotic disorder and/or a cancer;
wherein the inflammatory disease or disorder and/or the immune disease or disorder comprise rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft-versus-host disease;
wherein the fibrotic disorder comprises idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis, liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery; and
wherein the cancer comprises (i) a malignant new growth that arises from epithelium, found in skin or the lining of breast, ovary, prostate, lung, kidney, pancreas, stomach, bladder or bowel and/or (ii) bone, liver, lung or brain cancer.